$1.14 Billion is the total value of BVF INC/IL's 57 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 16.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CCXI | Sell | CHEMOCENTRYX INC | $85,620,000 | -7.6% | 6,773,760 | -3.7% | 7.52% | -16.8% |
| CYTK | Sell | CYTOKINETICS INC | $51,090,000 | +10.9% | 5,186,839 | -6.6% | 4.49% | -0.2% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $46,701,000 | +13.7% | 598,267 | -7.5% | 4.10% | +2.4% |
| KURA | Sell | KURA ONCOLOGY INC | $35,277,000 | -5.8% | 2,015,856 | -2.0% | 3.10% | -15.2% |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $34,068,000 | -7.2% | 723,322 | -2.9% | 2.99% | -16.5% |
| ARQL | Sell | ARQULE INC | $32,986,000 | -19.9% | 5,827,902 | -21.8% | 2.90% | -27.9% |
| XNCR | Sell | XENCOR INC | $32,639,000 | +1.4% | 837,538 | -3.7% | 2.87% | -8.7% |
| IONS | Sell | IONIS PHARMACEUTICALS INC | $26,822,000 | +12.9% | 520,000 | -8.8% | 2.36% | +1.7% |
| ANAB | Sell | ANAPTYSBIO INC | $24,969,000 | +4.8% | 250,265 | -25.4% | 2.19% | -5.6% |
| CNCE | Sell | CONCERT PHARMACEUTICALS INC | $23,627,000 | -22.7% | 1,592,138 | -12.4% | 2.08% | -30.5% |
| FWP | Sell | FORWARD PHARMA A/Ssponsored adr | $19,387,000 | -16.2% | 8,502,925 | -0.0% | 1.70% | -24.5% |
| VSTM | Sell | VERASTEM INC | $14,406,000 | -6.6% | 1,986,994 | -11.4% | 1.27% | -15.9% |
| OMED | Sell | ONCOMED PHARMACEUTICALS INC | $8,571,000 | -9.5% | 4,042,989 | -1.4% | 0.75% | -18.5% |
| ALBO | Sell | ALBIREO PHARMA INC | $7,212,000 | -7.7% | 218,800 | -0.5% | 0.63% | -16.8% |
| ADRO | Sell | ADURO BIOTECH INC | $2,115,000 | +2.1% | 287,776 | -2.8% | 0.19% | -7.9% |
| TOCA | Exit | TOCAGEN INC | $0 | – | -471,007 | -100.0% | -0.43% | – |
| GTXI | Exit | GTX INC DEL | $0 | – | -386,134 | -100.0% | -0.58% | – |
| IRWD | Exit | IRONWOOD PHARMACEUTICALS INC | $0 | – | -606,715 | -100.0% | -1.13% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-13 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.